Evidence map›Paper›PMID 32010361›Full record

ArticleActa endocrinologica (Bucharest, Romania : 2005)

LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW.

A Croitoru, I Dinu, V Herlea, G Becheanu, M Grasu, I Lupescu, S O Dima, F Buica, T Dumitrascu, C Lungulescu and 4 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

A CroitoruFundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.
I DinuFundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.
V HerleaFundeni Clinical Institute - Department of Pathology, Bucharest, Romania.
G BecheanuFundeni Clinical Institute - Department of Pathology, Bucharest, Romania.
M GrasuFundeni Clinical Institute - Department of Radiology and Medical Imaging, Bucharest, Romania.
I LupescuFundeni Clinical Institute - Department of Radiology and Medical Imaging, Bucharest, Romania.
S O DimaFundeni Clinical Institute - Center of General Surgery and Liver Transplantation, Bucharest, Romania.
F BuicaFundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.
T DumitrascuFundeni Clinical Institute - Center of General Surgery and Liver Transplantation, Bucharest, Romania.
C LungulescuDolj County Emergency Hospital - Department of Oncology, Craiova, Romania.
V M CroitoruFundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.
A TanaseFundeni Clinical Institute - Bone Marrow Transplant Center, Bucharest, Romania.
S M Negru"Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
I M GramaticuFundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.
Titu Maiorescu University · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 55-year-old-male with a large cell metastatic pancreatic neuroendocrine carcinoma treated for 14 months with lanreotide autogel having a stable disease (SD) and not responding to chemotherapy. The somatostatin analogues (SSA) were introduced after an episode of diarrhea and controlled the disease. Progression-free survival (PFS) as determined by Computerized Tomography (CT) scans was obtained for 14 months. After more than a year, the patient's health state deteriorated along with progressive disease. The capecitabine-temozolomide regimen was challenged, but after three cycles, a rapid clinical decline was noted.

conclusionThis unexpected event (diarrhea) in the course of the disease could represent the beginning of carcinoid syndrome. While the lanreotide autogel helped the episode of diarrhea pass, it also helped gain control over the disease itself.

Indexed as

lanreotide autogelLarge cell pancreatic carcinomaNueorendocrine tumor

Identifiers

PMID32010361
PMCPMC6992400
OpenAlexW3003230152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.